Growth hormone responses to hp GRF 1-44 amide, bromocriptine and stress in acromegaly are correlated.
The results of testing growth hormone (GH) reserve using human pancreatic growth hormone-releasing factor 1-44 amide (hp GRF 1-44 amide) have been compared with the GH responses in a variety of other dynamic tests in seven acromegalic patients. The GH release following hp GRF 1-44 amide correlated with the GH suppression following bromocriptine, but showed an inverse correlation with the GH release following stress tests (insulin-induced hypoglycaemia/glucagon). There was no correlation between the GH responses in these three tests and any of the other tests: TRH, GnRH and glucose. A hypothesis is proposed to explain these findings on the basis of varying degrees of GH secretion from adenomatous and normal pituitary somatotrophs in acromegaly.
D000172:Acromegaly / Q000378:metabolism*; D000328:Adult; D001971:Bromocriptine / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010187:Pancreatic Hormones / Q000493:pharmacokinetics*; D012636:Secretory Rate / Q000187:drug effects; D013312:Stress, Physiological
D010187:Pancreatic Hormones; D001971:Bromocriptine; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone